Orna Therapeutics Stock

ornatx.comHealthcare / BioTech & PharmaFounded: 2019

Ornatherapeutics, a biotech company headquartered in Cambridge Massachusetts, designs and engineers circular RNA (oRNA) therapeutics that treat various diseases. Ornatherapeutics proprietary disease fighting solutions includes protein expressions used as a delivery method for these solutions. Orna Therapeutics uses three processes, expression of its molecular materials, delivery of these materials, and optimazation of its process through research and development.

Register To Buy and Sell Shares

For more details on financing and valuation for Orna Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Orna Therapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Orna Therapeutics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Orna Therapeutics investors also invested in these private companies

Team

Management Team

Thomas Barnes, PhD
Chief Executive Officer
Amy Becker, PhD
Director, Immunology
Nelson Chau, PhD
Senior Vice President, Platform
Claudia Harper, DVM
Senior Vice President, Preclinical Safety
Nishla Keiser, PhD, JD
Chief Legal Strategy Officer
Robert Mabry, PhD
Chief Scientific Officer
Benjamin Maynor, PhD
Senior Vice President, CMC
John McCabe, CPA
Chief Financial Officer
Liz Molano
Head of People and Culture

Board Members

Daniel Anderson, PhD
Professor, Massachusetts Institute of Technology
Sakae Asanuma, CFA
President, Taiho Ventures
Thomas Ebeling
MPM Capital

Frequently Asked Questions About Orna Therapeutics’ Stock

plusminus
Can you buy Orna Therapeutics’ stock?
Orna Therapeutics is not publicly traded on NYSE or NASDAQ in the U.S. To buy Orna Therapeutics’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Orna Therapeutics’ stock?
Yes, you can sell stock of a private company like Orna Therapeutics. Forge can help you sell your Orna Therapeutics stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Orna Therapeutics’ stock price?
Orna Therapeutics is a privately held company and therefore does not have a public stock price. However, you may access Orna Therapeutics’ private market stock price with Forge Data.
plusminus
What is Orna Therapeutics’ stock ticker symbol?
Orna Therapeutics does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Merck (MRK) Enters Into Circular RNA Collaboration With Orna
Merck (MRK) is set to make an upfront payment of $150 million to Orna for rights to the latter's circular RNA technology to make vaccines and therapeutics for infectious disease and oncology.
Orna Therapeutics Raises $221M in Series B Financing
Orna Therapeutics, a Cambridge, MA-based biotechnology company pioneering a new class of fully engineered circular RNA therapies (oRNA), raised $221m in Series B funding.
Updated on: Feb 21, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.